# Guangdong Hengrui Pharmaceutical Co., Ltd trials: 59 (2026)

ClinicalTrials.gov lists 59 trials with Guangdong Hengrui Pharmaceutical Co., Ltd as lead sponsor, 25 of them recruiting or not yet recruiting.

## The full list

Clinical trials led by Guangdong Hengrui Pharmaceutical Co., Ltd: 59 rows for $5, every trial on ClinicalTrials.gov. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/guangdong-hengrui-pharmaceutical-co-ltd

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 59
- Recruiting or not yet: 25
- Read on: November 19, 2026

## Trials

The 25 newest of 59, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 6, 2026 | NCT07923851 | A Trial Evaluating the Efficacy and Safety of SHR-1139 Injection in Adult Patients With Palmoplantar Pustulosis | Guangdong Hengrui Pharmaceutical Co., Ltd | Phase 2 | Not yet recruiting | Palmoplantar Pustulosis of Adults | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07923851) |
| September 17, 2026 | NCT07826364 | A Randomized, Double-Blind, Dose-Escalation, Placebo-Controlled Study of SHR-1179 Injection in Participants With Obesity | Guangdong Hengrui Pharmaceutical Co., Ltd | Phase 1 | Not yet recruiting | Body Weight Management | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07826364) |
| August 11, 2026 | NCT07758101 | A Study to Evaluate the Safety of SHR-7590 in Chinese Healthy Participants and in Patients With Moderate-to-severe Inflammatory Bowel... | Guangdong Hengrui Pharmaceutical Co., Ltd | Phase 1 | Recruiting | Moderate-to-severe Inflammatory Bowel Disease | 88 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07758101) |
| August 11, 2026 | NCT07758075 | A Phase II Clinical Study to Evaluate the Efficacy and Safety of SHR-1139 Injection in Patients With Plaque Psoriasis | Guangdong Hengrui Pharmaceutical Co., Ltd | Phase 2 | Not yet recruiting | Plaque Psoriasis | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07758075) |
| August 6, 2026 | NCT07749651 | A Study on the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of SHR-7012 in Healthy Adults | Guangdong Hengrui Pharmaceutical Co., Ltd | Phase 1 | Recruiting | Cutaneous Lupus Erythematosus(CLE) | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07749651) |
| July 22, 2026 | NCT07719530 | Phase II Clinical Trial of SHR-1139 Injection in Patients With Psoriasis | Guangdong Hengrui Pharmaceutical Co., Ltd | Phase 2 | Recruiting | Psoriasis | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07719530) |
| July 14, 2026 | NCT07701239 | A Study Comparing a Pre-filled Safety Syringe and an Autoinjector for SHR-1703 Injection in Healthy Participants | Guangdong Hengrui Pharmaceutical Co., Ltd | Phase 1 | Not yet recruiting | Asthma With Eosinophilic Phenotype | 84 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07701239) |
| July 7, 2026 | NCT07688772 | A Clinical Study Evaluating the Efficacy and Safety of SHR-1819 Injection in Patients With Seasonal Allergic Rhinitis | Guangdong Hengrui Pharmaceutical Co., Ltd | Phase 3 | Active not recruiting | Seasonal Allergic Rhinitis | 220 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07688772) |
| June 10, 2026 | NCT07640451 | A Clinical Trial to Evaluate the Efficacy and Safety of HRS-9821 Inhalation Suspension in Patients With Moderate to Severe Chronic... | Guangdong Hengrui Pharmaceutical Co., Ltd | Phase 2 | Recruiting | COPD | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07640451) |
| June 3, 2026 | NCT07622342 | A Phase II Study of SHR-2173 Injection in Patients With Myasthenia Gravis | Guangdong Hengrui Pharmaceutical Co., Ltd | Phase 2 | Recruiting | Generalized Myasthenia Gravis | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07622342) |
| May 5, 2026 | NCT07567872 | A Phase I Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HRS-9821 Powder for Inhalation Administered as... | Guangdong Hengrui Pharmaceutical Co., Ltd | Phase 1 | Recruiting | COPD | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07567872) |
| March 3, 2026 | NCT07444684 | A Study to Evaluate SHR-1139 Injection in Patients With Pyoderma Gangrenosum | Guangdong Hengrui Pharmaceutical Co., Ltd | Phase 2 | Not yet recruiting | Pyoderma Gangrenosum | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07444684) |
| January 21, 2026 | NCT07354932 | A Study of SHR-2173 in Participants With Primary IgA Nephropathy | Guangdong Hengrui Pharmaceutical Co., Ltd | Phase 2 | Recruiting | Primary IgA Nephropathy | 84 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07354932) |
| January 7, 2026 | NCT07321951 | A Study of SHR-1819 in Patients With Moderate-to-severe Atopic Dermatitis | Guangdong Hengrui Pharmaceutical Co., Ltd | Phase 2 | Active not recruiting | Moderate-to-severe Atopic Dermatitis | 201 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07321951) |
| December 30, 2025 | NCT07309055 | A Study of SHR-1819 Injection in Adolescents With Severe Atopic Dermatitis | Guangdong Hengrui Pharmaceutical Co., Ltd | Phase 3 | Recruiting | Adolescents With Moderate-to-severe Atopic Dermatitis | 201 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07309055) |
| December 23, 2025 | NCT07299422 | A Study of SHR-2173 in Participants With Systemic Lupus Erythematosus | Guangdong Hengrui Pharmaceutical Co., Ltd | Phase 2 | Recruiting | Systemic Lupus Erythematosus | 248 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07299422) |
| December 17, 2025 | NCT07289763 | Phase II Randomized, Open-label, Multicenter Clinical Study Evaluating the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of... | Guangdong Hengrui Pharmaceutical Co., Ltd | Phase 2 | Recruiting | Primary Membranous Nephropathy | 75 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07289763) |
| December 4, 2025 | NCT07264335 | A Study on the Bioavailability of SHR-1819 Injection Administered Subcutaneously Using Different Injection Devices in Healthy Subjects | Guangdong Hengrui Pharmaceutical Co., Ltd | Phase 1 | Completed | Atopic Dermatitis | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07264335) |
| November 18, 2025 | NCT07233655 | A Phase II Trial of SHR-3045 Injection in Patients With Rheumatoid Arthritis | Guangdong Hengrui Pharmaceutical Co., Ltd | Phase 2 | Active not recruiting | Moderate to Severe Active Rheumatoid Arthritis | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07233655) |
| November 18, 2025 | NCT07232576 | A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of SHR-1139 in Patients With Moderate-to-severe Active Ulcerative... | Guangdong Hengrui Pharmaceutical Co., Ltd | Phase 2 | Active not recruiting | Adult Patients With Moderately to Severely Active Ulcerative Colitis | 21 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07232576) |
| November 17, 2025 | NCT07229742 | A Phase II Clinical Study on the Efficacy and Safety of SHR-2173 Injection in the Treatment of Patients With Active Lupus Nephritis | Guangdong Hengrui Pharmaceutical Co., Ltd | Phase 2 | Recruiting | Active Lupus Nephritis | 51 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07229742) |
| November 17, 2025 | NCT07229716 | Study on the Drug Interactions of HRS-9813, Pirfenidone and Nintedanib in Healthy Subjects | Guangdong Hengrui Pharmaceutical Co., Ltd | Phase 1 | Completed | Pulmonary Fibrosis | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07229716) |
| October 8, 2025 | NCT07211542 | A Study to Investigate the Efficacy and Safety of SHR-1905 in Patients With Moderate-to-severe Atopic Dermatitis | Guangdong Hengrui Pharmaceutical Co., Ltd | Phase 2 | Recruiting | Moderate-to-severe Atopic Dermatitis | 75 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07211542) |
| October 3, 2025 | NCT07206758 | Phase I Study of SHR-2173 Injection in Patients With Primary Immune Thrombocytopenia | Guangdong Hengrui Pharmaceutical Co., Ltd | Phase 1 | Recruiting | Immune Thrombocytopenia | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07206758) |
| October 1, 2025 | NCT07200596 | The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of SHR-3045 in Healthy Subjects | Guangdong Hengrui Pharmaceutical Co., Ltd | Phase 1 | Completed | Rheumatoid Arthritis (RA) | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07200596) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 26 |
| Phase 1/2 | 1 |
| Phase 2 | 24 |
| Phase 2/3 | 2 |
| Phase 3 | 6 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 26 |
| Recruiting | 19 |
| Active not recruiting | 7 |
| Not yet recruiting | 6 |
| Terminated | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Pulmonary Disease, Chronic Obstructive | 4 |
| Idiopathic Pulmonary Fibrosis | 3 |
| Glomerulonephritis, IGA | 3 |
| Pulmonary Fibrosis | 2 |
| Asthma | 2 |
| Rhinitis, Allergic, Seasonal | 2 |
| Chronic Cough | 2 |
| Arthritis, Rheumatoid | 2 |
| Lupus Erythematosus, Systemic | 2 |
| Myasthenia Gravis | 1 |
| Lupus Erythematosus, Cutaneous | 1 |
| Pyoderma Gangrenosum | 1 |
| Purpura, Thrombocytopenic, Idiopathic | 1 |
| Psoriasis | 1 |
| Dermatitis, Atopic | 1 |
| Churg-Strauss Syndrome | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Energy companies in the United States](https://specstream.ai/data/businesses/energy-companies/united-states)
- [Adult education centers in the United States](https://specstream.ai/data/businesses/adult-education-centers/united-states)
- [Pan Asian restaurants in the United States](https://specstream.ai/data/businesses/pan-asian-restaurants/united-states)
- [Equipment rental companies in the United States](https://specstream.ai/data/businesses/equipment-rental-companies/united-states)
- [Air duct cleaning companies in the United States](https://specstream.ai/data/businesses/air-duct-cleaning-companies/united-states)
